Pakistan is one of the six countries that account for more than 50 percent of the world’s maternal deaths. According to Population Council estimates, each year nearly 8.6 million women become pregnant in the country. Of these, 1.2 million women are likely to face obstetric complications. Each year, there are nearly 14,000 pregnancy-related deaths. Information is lacking on context-specific health-system barriers that prevent optimal use of the lifesaving medicine magnesium sulfate (MgSO4) in Pakistan. Although efforts in Pakistan both at the national and subnational level are ongoing on the prevention and treatment of pre-eclampsia and eclampsia (PE/E), results are generally suboptimal and program interventions remain uncoordinated and fragmented. A fragmented system for registration, procurement, and distribution is at the source of the low use of magnesium sulfate, even though policies are all aligned with international standards. To fully appreciate the enormity of the problem at the country level, this systematic review of published papers on PE/E was conducted in Pakistan from 2005 to 2015 to understand key challenges, gaps, and interventions related to the prevention and treatment of pre-eclampsia and eclampsia.
Shaikh, Saleem and Ali M. Mir. 2016. "A systematic review of the treatment and management of pre-eclampsia and eclampsia in Pakistan." Islamabad: Population Council.